You have to wonder just what the value is of all these patents. I would guess that most of them are worthless and definitely not worth the cost of their prosecution.
But the other side of that is if one of them blocks launch of a competing generic ala aL, then it pays for a lot of misses.
IF the patent blocking of generic L versions hold up, it would add a lot of value to MNTA which could trigger a take over.
Hopefully the same will happen on generic versions of Copaxone.
Market Data 
Markets 
AI
